A phase I and pharmacologie study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 1, 2005, Pages 91-99

  Planting, A S T ^a   Sonneveld, P ^a   Van Der Gaast, A ^a   Sparreboom, A ^a   Van Der Burg, M E L ^a   Luyten, G P M ^a   De Leeuw, K ^a   De Boer Dennert, M ^a   Wissel, P S ^b   Jewell, R C ^b   Paul, E M ^b   Purvis Jr , N B ^c   Verweij, J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b GLAXOSMITHKLINE   (United States)

^c Esoterix Oncology   (United States)

Author keywords

Doxorubicin; GF120918; MDR converter; Phase I

Indexed keywords

DOXORUBICIN; DOXORUBICINOL; ELACRIDAR; ACRIDINE DERIVATIVE; ANTINEOPLASTIC ANTIBIOTIC; GLYCOPROTEIN P; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADULT; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL DISEASE; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTIDRUG RESISTANCE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; SOMNOLENCE; STEADY STATE; VOMITING; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG INTERACTION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; NEOPLASM; ORAL DRUG ADMINISTRATION;

ACRIDINES; ADMINISTRATION, ORAL; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; P-GLYCOPROTEIN; TETRAHYDROISOQUINOLINES;

EID: 19944427647     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0854-6     Document Type: Article

References (35)

1. Baldini N, Scotlandi K, Barbanti-Brodano G, Manarca MC, Maurici D, Bacci G, Bertoni F, Picci P, Sotilli S, Campanacci M, Serra M (1995) Expression of P-glycoprotein in high-grade osteosarcoma in relation to clinical outcome. N Engl J Med 333:1380-1385
2. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Elisar MN, Halsey J, Sikic BI (1994) Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12:835-842
3. Campos L, Guyotat D, Archambaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D (1992) Clinical significance of multidrug resistance and P-glycoprotein expression on acute non-lymphoblastic leukemia cells at diagnosis. Blood 79:473-476
4. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BG, Taylor CW, Miller TP, Salmon SE (1989) Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7:415-424
5. De Bruin P, Verweij J, Loos WJ, Kolker HJ, Planting AST, Nooter K, Stoter G, Sparreboom A (1999) Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography. Anal Biochem 266:216-221
6. Dorr R, Karanes C, Spier C, Grogan T, Greer J, Moore J, Weinberger B, Schiller G, Pearce T, Litchman M, Dalton W, List AF (2001) Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. J Clin Oncol 19:1589-1599
7. Ford JM, Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42:155-199
8. Germann UA (1996) P-glycoprotein - a mediator of multidrug resistance in tumour cells. Eur J Cancer 32A(6):927-944
9. Giaccone G, Linn SC, Welink L, Catimel G, Stieltjes H, van der Vijgh WJF, Eeltink C, Vermerken JB, Pinedo HM (1997) A dose-finding and pharmacologic study of reversal of multidrug resistance with SDZ PSC-833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 3:2005-2015
10. Gianni L, Munzone E, Capri G, Fulfaro F, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C, Stefanelli A, Valagussa P, Bonnadonna G (1995) Paclitaxel by 3-h infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: a high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699
11. Gonzalez O, Colombo T, De Fusco M, Imperatori L, Zuccheti M, Dincali M (1995) Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemother Pharmacol 36:335-340
12. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427
13. Hu XF, Slater S, Wall DM, Kantharides P, Parkin JD, Cowman A, Zalcberg JR (1995) Rapid upregulation of MDR1 expression by anthracyclines in a classical multidrug-resistant cell line. Br J Cancer 71:931-936
14. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridinecarboxamide derivative. Cancer Res 53:4595-4602
15. Kerr DJ, Graham J, Cummings J, Morrison JG, Thompson GB, Brodie MJ, Kaye SB (1986) The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 8:239-242
16. Levine EA, Holzmayer T, Bacus S, Mechetner E, Mera R, Bolliger C, Roninson IB, Das Gupta TK (1997) Evaluation of newer prognostic markers for adult soft tissue sarcomas. J Clin Oncol 15:3249-3257
17. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI (1992) Alteration of etoposide pharmacokinetics by cyclosporin in a phase I trial to modulate multidrug resistance. J Clin Oncol 10:1635-1642
18. Minotti G, Cavaliere AF, Mordente A, Rossi M, Schiavello R, Zamparelli R, Possati G (1995) Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity. J Clin Invest 95:1595-1605
19. Nooter K, Herweijer H (1991) Multidrug resistance (mdr) genes in human cancer. Br J Cancer 63:663-669
20. Nooter K, Sonneveld P (1994) Clinical relevance of P-glycoprotein expression in hematologic malignancies (review). Leuk Res 18:233-243
21. Ozols RF, Cunnion RE, Klecker RW Jr, Hamilton TC, Ostchega Y, Parillo JE, Young RC (1987) Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5:641-647
22. Pastan I, Gottesman M (1987) Multiple-drug resistance in human cancer. N Engl J Med 316:1388-1393
23. Raderer M, Schethauer W (1993) Clinical trials of agents that reverse multidrug resistance. Cancer 72:3553-3563
24. Rubin EH, de Alwis DP, Pouliquen I, Green L, Marder P, Lin Y, Musanti R, Grospe S, Smith S, Toppmeyer D, Much J, Kane M, Chaudary A, Jordan C, Burgess M, Slapak C (2002) A phase I trial of a potent P-glycoprotein inhibitor, zosuquidar.3HC1 trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. Clin Cancer Res 8:3710-3717
25. Solary E, Caillot D, Chauffert B, Casanovas RO, Dumas M, Maynadie M, Guy H (1992) Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 10:1730-1736
26. Sonneveld P, Durie BGM, Lokhorst HM, Marie JP, Solbu G, Suciu S, Zittoun R, Lowenberg B, Nooter K (1992) Modulation of multidrug-resistant multiple myeloma by cyclosporine. Lancet 340:255-259
27. Sparreboom A, Planting AST, Jewell RC, van der Burg MEL, van der Gaast A, de Bruijn P, Loos WJ, Nooter K, Chandler LH, Paul EM, Wissel PS, Verweij J (1999) Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anticancer Drugs 10:719-728
28. Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JC, Rey M, Sanger J, Kramer E, Ferrans, V Hochster H, Meyers M, Blum RH, Feit F, Attubato M, Burrows W, Muggia FM (1992) ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10:117-127
29. Stupp R, Bauer J, Pagani O, Gerard B, Cerny T, Sessa C, Bastian G, Sarkany M, Schlapfer J, Giroux B, Leyvraz L (1998) Ventricular arrhythmia and torsade de pointes: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. Ann Oncol 9:1233-1242
30. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA (1997) Cardioprotection with dexrazoxane for doxorubicin containing therapy in advanced breast cancer. J Clin Oncol 15:1318-1332
31. Tolcher AW, Cowan KH, Solomon D, Ognibene F, Goldspiel B, Chang R, Noone MH, Denicoff AM, Barnes CS, Gossard MR, Fetsch PA, Berg SL, Balis FM, Venzon DJ, O'Shaugnessy JA (1996) Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. J Clin Oncol 14:1173-1184
32. Van Asperen J, Van Tellingen O, Tijssen F, Schinkel AH, Beijnen JH (1999) Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdrla P-glycoprotein. Br J Cancer 79:108-113
33. Verweij J, Herweijer H, Oosterom R, van der Burg MEL, Planting AST, Seynaeve C, Stoter G, Nooter K (1991) A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. Br J Cancer 64:361-364
34. Wishart GC, Bisset D, Paul J, Jodrell D, Harnett A, Habeshaw T, Kerr DJ, Macham MA, Soukop M, Leonard RCF, Knepil J, Kaye SB (1994) Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol 12:1771-1777
35. Witherspoon SM, Emerson DL, Kerr BM, Lloyd TL, Dalton WS, Wissel PS (1996) Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG 918. Clin Cancer Res 1:7-12